Meyka AI API is live for developers.Start building.
Advertisement
Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. (ITCI) Stock Competitors & Peer Comparison

See (ITCI) competitors and their performances in Stock Market.

ITCINASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$131.87
$0.00(0.00%)
U.S. Market opens in 59h 10m
Advertisement

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
ITCI$131.87+0.00%14B-180.64-$0.73N/A
TAK$15.56+3.49%48.8B41.78$0.37+4.03%
TEVA$34.56+5.25%40.1B25.69$1.34N/A
HLN$9.08+4.13%39.9B17.96$0.50+2.16%
VTRS$16.09+3.41%18.5B-53.00-$0.30+3.01%
ELAN$24.88+1.26%12.3B-49.39-$0.50N/A
CTLT$63.48+0.00%11.5B-27.84-$2.28N/A
RDY$13.33+2.34%11B24.50$0.54+0.69%
RGC$21.70-8.63%11B-2216.00-$0.01N/A
LNTH$102.87+2.61%6.7B24.54$4.19N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

ITCI vs TAK Comparison June 2026

ITCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ITCI stands at 14B. In comparison, TAK has a market cap of 48.8B. Regarding current trading prices, ITCI is priced at $131.87, while TAK trades at $15.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ITCI currently has a P/E ratio of -180.64, whereas TAK's P/E ratio is 41.78. In terms of profitability, ITCI's ROE is -0.09%, compared to TAK's ROE of +0.03%. Regarding short-term risk, ITCI is less volatile compared to TAK. This indicates potentially lower risk in terms of short-term price fluctuations for ITCI.Check TAK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions